There is an unmet medical need to improve the treatment of patients with established atherosclerotic cardiovascular disease (ASCVD), especially those with chronic kidney disease (CKD), and thereby reduce their risk of cardiovascular (CV) events.  Inflammation is an additional important risk factor to address in patients with ASCVD at high risk of major adverse cardiovascular events (MACE).

The primary objective of this study is to demonstrate the superiority of the study drug given once monthly in reducing the risk of major adverse cardiovascular events when compared to placebo, both added to standard of care, in participants with established ASCVD, CKD and systemic inflammation.  Standard of care treatment will be maintained throughout the study for all participants.

Qualified participants will:

• See a physician at no cost
• Receive pertinent tests and imaging at no cost
• Receive compensation for time and travel  

HIV (human immunodeficiency virus) is a virus that attacks the body’s immune system. If HIV is not treated, it can lead to AIDS (acquired immunodeficiency syndrome).  There is currently no effective cure. Once people get HIV, they have it for life.  But with proper medical care, HIV can be controlled. People with HIV who get effective HIV treatment can live long, healthy lives and protect their partners.

This research study is testing an investigational drug in people who have never taken any antiretroviral therapies (ART) to treat their HIV.  Researchers will assess how well it slows the growth of the HIV virus, and how it works in the body compared to an approved 3-drug medicine.

The study will last approximately 2 yrs with 13 clinic visits. 

A few qualifications to participate are: 

• HIV-1 positive adults
• Have not taken any ART medications since being diagnosed with HIV

Qualified participants will:

• See a physician at no cost
• Receive medication and labs at no cost
• Receive compensation for time and travel  

Cardiovascular disease (CVD) is the leading cause of mortality and morbidity; globally, 121.5 million people suffered from CVD in 2016 and the incidence increased with age in both men and women. The burden of CVD is significant for patients as well as society. CVDs are the number one cause of death globally. An estimated 17.9 million people died from CVDs in 2016, representing 31% of all global deaths. Of these deaths, 85% were due to heart attack and stroke. CVD is expected to account for >22.2 million deaths in 2030. Despite efforts to improve acute treatment, as well as both primary and secondary prevention which has resulted in better outcomes, many of the underlying risk factors and underlying conditions are increasing. Cardiovascular risk factors include hypertension and hyperlipidemia, but also diseases such as obesity, type 2 diabetes (T2D) and renal impairment, where the two latter diseases even have specific prevention goals in the guidelines on CVD prevention.

We are doing this study to see if CagriSema, a new medicine intended for the treatment of obesity, is safe for use in people living with obesity and cardiovascular disease. The study will also include people with type 2 diabetes and/or chronic kidney disease.

You may qualify if:

• You have had a stroke, a heart attack (myocardial infarction), or have poor circulation (peripheral arterial disease)
• You are 55 years of age or older
• You are overweight or obese
• You have Type 2 Diabetes and/or chronic kidney disease

Qualified participants will:

• See a physician at no cost
• Receive medication that may help with weight loss
• Routine meetings with a Registered Dietician

Receive compensation for time and travel

HIV infection is a chronic condition that remains a major global health problem, with an estimated 38.4 million people world-wide living with the infection.  Antiretroviral Therapy (ART) can suppress HIV replication and significantly decrease AIDS-related mortality and improve lives for people living with HIV, but these regimens cannot eliminate HIV in the cells. Strictly adhering to lifelong ART (which is very challenging and stigmatizing) is required to maintain viral suppression, prevent resistance to ART and prevent HIV transmission.  Removing the need for chronic ART treatment would revolutionize the standard of care for people living with HIV.  Meeting these needs should considerably ease patients' stigma burden, lessen long-term health problems due to HIV including the effects of chronic immune activation/inflammation, and eliminate ART associated toxicity and resistance. Importantly, sustained ART-free HIV control may represent a more reliable approach to reducing HIV transmission and have a large impact on public health. Sustained ART-free immune virologic control, if continued over time, may contribute to the achievement of complete cure. 

This research study will test two investigational drugs that are not approved by the Food and Drug Administration (FDA) to treat people living with HIV.  The main objectives of this trial are to evaluate the effectiveness, safety and how well tolerated the 2 investigational drugs are versus placebo in people living with HIV who are on stable ART undergoing treatment interruption.

Potentially qualified participants will: 

• Be adults of any sex and gender, 18 to 70 years of age, inclusive, at the time of screening
• Be on the same Antiretroviral Therapy regimen for at least 8 weeks, and on ART for at least 12 months, and it has been keeping your viral load undetectable.
• Not be on long acting or injectable ART in the past 6 months

Qualified participants will:

• See a physician and receive study medication at no cost
• Receive compensation for time and travel